Comparative Pharmacology
Head-to-head clinical analysis: HICON versus PRANTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HICON versus PRANTAL.
HICON vs PRANTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Prantal (diphemanil methylsulfate) is a quaternary ammonium anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors (M1, M2, M3 subtypes), reducing gastrointestinal motility, gastric acid secretion, and bronchial secretions. It does not cross the blood-brain barrier.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
50-100 mg orally 3-4 times daily; maximum 600 mg/day
None Documented
None Documented
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 4-6 hours; steady-state achieved within 24 hours in patients with normal renal function.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Primarily renal (50-70% unchanged) with minor biliary excretion; fecal elimination accounts for approximately 10-20%.
Category C
Category C
Anticholinergic
Anticholinergic